ArticleFrontiers in oncology2025
Co-morbid diabetes mellitus in cancer patients undergoing treatment: a case series and perspective.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Diabetes mellitus (DM) is frequently diagnosed among cancer patients on treatment, which suggests a concomitant underlying mechanism. DM is found among 8 to 18% of cancer patients. The initiation of cancer treatment is linked with the onset of diabetes. This study aims to assess the variation in blood glucose levels of cancer patients during the course of their treatment. Methods: A hospital record based cross-sectional study was conducted from November 2024 to January 2025, among 50 cancer patients on treatment at Sammprada cancer hospital, Bangalore, India. From the initial 50 cancer patients, a series of 11 cases with large variation in blood glucose levels were included in the study. These include new onset or old cases of diabetes, with blood glucose levels measured across 6 timeframes during the course of cancer treatment. Results: For the initial 50 patients, the measure of central tendency seemed regressed to the mean. Hence, the design of study was changed from cross-sectional to a case series. For the series of 11 patients all of whom had advanced stage cancer, 5 patients (2 males, 3 females) had history of diabetes and 2 female patients were incident cases of diabetes (1 each in endocrine and cervical cancer). Also, the treatment for diabetes was revised or newly initiated for a total of 5 patients (4 females, 1 male). Conclusion: Among the 11 cancer patients, 5 had history of DM and 2 were incident cases of DM. Healthcare providers should regularly screen the levels of blood glucose during the continuum of cancer care and monitor the change in trend.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.